Cortellis Generics Intelligence & Global Pricing Trends

Make life-saving treatments more accessible

Make timely and data-driven business decisions in the highly competitive and fast-changing generics and biosimilars markets with a comprehensive, single source of market performance, patent and manufacturing data.

Have confidence you’re making the most informed IP, sourcing, portfolio and business development decisions using reliable and integrated data in a single, easily searchable solution. Strategically develop your portfolio, find API suppliers, gain insight on when drugs lose exclusivity and monitor your competition.

How we help

Pinpoint when a drug will go generic to expand your portfolio
Identify when a drug will lose exclusivity and identify new launch opportunities using expertly curated and searchable data compiled into a Constraint Date Forecast and Product Selector Tool.
Efficiently plan launches
Make data-driven decisions to inform your launch strategies, sales forecasts and commercial plans with easily accessible and digestible global sales, kg consumption, pack price and market share data all in a single, trusted solution.
Understand global pricing trends
Inform product selection or portfolio rationalization with a better understanding of market dynamics, dose form advantage and reimbursement trends provided by comparable currency and historical pricing data.

Why choose us

All-inclusive data in a single, integrated location

72K+ companies, including API and dose manufacturers
61 K+ small molecules and biologics
26 K+ supplementary protection certificates
1.1M+ worldwide patents, including patent families, SPCs and patent litigation
18 K+ synthesis schemes

Global Pricing Trends

Optional module to optimize pricing strategies, anticipate payer pressure, determine impact on market access and plan future launches
Pricing and reimbursement intelligence of final dose formulations across 90+ markets
Historical market share and pricing data of up to 5 years for United States and Latin America markets

Easy-to-use, intuitive tools

Constraint Date Forecast:

Identifies earliest time a drug can enter the generic market
Based on several data sources such as constraining patents, exclusivities and SPCs
Includes one date for each country

Product and company selectors:

Provide ability to quickly identify new launch opportunities based on specific criteria
Connect ~50 product and company criteria around LOE, market potential and competitiveness

Timely updates and alerts

Daily updates for US patent challenges
Weekly updates for manufacturing and patent intelligence
Monthly or quarterly updates for market performance
Customizable email alerts for new or updated product or company data

“[Cortellis Generics Intelligence] is one the greatest tools for us to manage our suppliers in API business. [It] provides unique and serious data for those who are responsible in supply management, control and new product development.”

Managing Director – Asia Pacific
US-based pharmaceutical company

“We have had [Cortellis Generics Intelligence] for over 15 years. With competition at an all-time high, you need a place with direct information in one spot.”

Business Development and Licensing
Pharmaceutical company

“Building and continually monitoring a differentiated product portfolio is critical for us, and Clarivate has helped us do just that, which is essential to our growth.”

Chairman and CEO
Pharmaceutical company

“[Cortellis Generics Intelligence] provides a wide range of information in one place, which is otherwise difficult to obtain. [It] saves substantial time and, at the same time, provides a thorough picture on the topics.”

Head of Patents
Pharmaceutical company

“When we plan [our] generic portfolio to enter U.S. and E.U. markets, we survey information on Cortellis Generics Intelligence.”

IP Analyst
Pharmaceutical company

“This platform is a one-stop shop for commercial as well as competitive information. It saves considerable time, it’s easy to navigate, it’s easy to download and use information as desired, and hence, it’s a productive and progressive tool for an organization.”